Clinical trial
Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer
NCT00470574 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00470574 |
|---|---|
| Title | Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer |
| Official title | Pilot Study of Immunization of High Risk Breast Cancer Patients With a Sialyl Lewisª -Keyhole Limpet Hemocyanin Conjugate Plus the Immunological Adjuvant QS-21 |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Other |
| Interventions | QS21, sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine, immunoenzyme technique, immunologic technique, laboratory biomarker analysis |
| Enrollment | 7 |
| Start date | Mar 20, 2007 |
| Primary completion | Jan 24, 2020 |
| Completion | Jan 24, 2020 |
| First posted | May 7, 2007 |
| Last update posted | Nov 18, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: